Nabriva Therapeutics Equity 2024

Nabriva Therapeutics Aktienanalyse

What does Nabriva Therapeutics do?

Nabriva Therapeutics PLC is a biopharmaceutical company based in Dublin that focuses on the research, development, and marketing of antibiotics for medical needs. The company was founded in 2006 and has since become the leading provider of antibiotics for infectious diseases in Europe and the USA. Nabriva Therapeutics' business model aims to improve the production of antibiotics for acute infections and develop innovative drugs for use in clinical practice and emergency settings. It specializes in serious and life-threatening infections such as pneumonia, bacterial skin and soft tissue infections, and bacterial infections of the urinary tract. The company is divided into two business segments: antibody therapeutics and antibiotics. Antibody therapeutics stimulate the body's immune system to better fight pathogens, while antibiotics directly combat and inhibit the growth of bacteria. Nabriva Therapeutics' flagship product is the antibiotic Xenleta (Levofloxacin) for the treatment of pneumonia. Xenleta is a bactericidal antibiotic that is effective against a variety of difficult-to-treat pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus with reduced susceptibility to Vancomycin (VSSA), acting directly on bacteria. It has been reviewed and approved by the FDA. Nabriva Therapeutics has also advanced the development of Contepo (Fosfomycin) in the field of antibiotics. Contepo is a broad-spectrum antibiotic that is effective against gram-positive and gram-negative bacteria and is intended for the treatment of infectious diseases of the urinary tract. Nabriva Therapeutics has submitted a support application to the FDA for the approval of Contepo for the therapy of complicated urinary tract infections. In August 2020, Nabriva Therapeutics announced the completion of an agreement with Taiho Pharmaceutical Co., Ltd. to market Xenleta in Brazil. The company has also entered into a collaboration with Merck and Co.'s biopharmaceutical organization to investigate the potential of Xenleta for treating patients with diseases such as bacterial skin and soft tissue infections and lung infections. Overall, Nabriva Therapeutics has played an important role in the development of antibiotics for infectious diseases and the fight against antibiotic resistance. With its innovative products and collaboration with other biopharmaceutical organizations, Nabriva Therapeutics has improved its position in the industry and strengthened its leadership in the field of antibiotic therapy. Nabriva Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Nabriva Therapeutics's Equity

Nabriva Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Nabriva Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Nabriva Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Nabriva Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Nabriva Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Nabriva Therapeutics stock

What is the equity of Nabriva Therapeutics this year?

Nabriva Therapeutics has equity of 3.29 M USD this year.

What was the equity of Nabriva Therapeutics compared to the previous year?

The equity of Nabriva Therapeutics has increased/decreased by -93.83% decreased compared to the previous year.

What impact does a high equity have on investors of Nabriva Therapeutics?

A high equity is advantageous for investors of Nabriva Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Nabriva Therapeutics?

A low equity can be a risk for investors of Nabriva Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Nabriva Therapeutics affect the company?

An increase in equity of Nabriva Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Nabriva Therapeutics affect the company?

A reduction in equity of Nabriva Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Nabriva Therapeutics?

Some factors that can affect the equity of Nabriva Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Nabriva Therapeutics so important for investors?

The equity of Nabriva Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Nabriva Therapeutics take to change the equity?

To change equity, Nabriva Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Nabriva Therapeutics pay?

Over the past 12 months, Nabriva Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nabriva Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Nabriva Therapeutics?

The current dividend yield of Nabriva Therapeutics is .

When does Nabriva Therapeutics pay dividends?

Nabriva Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nabriva Therapeutics?

Nabriva Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Nabriva Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nabriva Therapeutics located?

Nabriva Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nabriva Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nabriva Therapeutics from 10/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.

When did Nabriva Therapeutics pay the last dividend?

The last dividend was paid out on 10/6/2024.

What was the dividend of Nabriva Therapeutics in the year 2023?

In the year 2023, Nabriva Therapeutics distributed 0 USD as dividends.

In which currency does Nabriva Therapeutics pay out the dividend?

The dividends of Nabriva Therapeutics are distributed in USD.